{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,12,14]],"date-time":"2022-12-14T05:45:00Z","timestamp":1670996700826},"reference-count":29,"publisher":"Editorial Committee of Japanese Journal of Infectious Diseases, National Institute of Infectious Dis","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Jpn J Infect Dis"],"published-print":{"date-parts":[[2021,9,30]]},"DOI":"10.7883\/yoken.jjid.2020.876","type":"journal-article","created":{"date-parts":[[2021,1,28]],"date-time":"2021-01-28T22:10:08Z","timestamp":1611871808000},"page":"429-436","source":"Crossref","is-referenced-by-count":0,"title":["The Immunogenicity and Safety Profile for KM-248, a Combined Measles, Mumps, and Rubella Vaccine, and Its Noninferiority to the Measles Vaccine in Healthy Japanese Children: a Phase 3 Randomized Multicenter Single-Blind Clinical Trial"],"prefix":"10.7883","volume":"74","author":[{"given":"Heather","family":"Platt","sequence":"first","affiliation":[{"name":"Merck & Co., Inc., USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinji","family":"Tochihara","sequence":"additional","affiliation":[{"name":"Development Department, KM Biologics Co., Ltd., Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshiaki","family":"Oda","sequence":"additional","affiliation":[{"name":"Clinical Development Department, KM Biologics Co., Ltd., Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kohji","family":"Ueda","sequence":"additional","affiliation":[{"name":"Kyushu University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"4631","reference":[{"key":"1","unstructured":"1. Redd SC, Markowitz LE, Katz SL. Measles vaccine. In: Plotkin SA, Orenstein WA, editors. Vaccines. 3rd ed. Philadelphia, PA: W.B. Saunders Company; 1999. p. 222-266."},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Plotkin SA, Wharton M. Mumps vaccine. In: Plotkin SA, Orenstein WA, editors. Vaccines. 3rd ed. Philadelphia, PA: W.B. Saunders Company; 1999. p. 267-292.","DOI":"10.1097\/00024382-199910000-00017"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Plotkin SA. Rubella vaccine. In: Plotkin SA, Orenstein WA, editors. Vaccines. 3rd ed. Philadelphia, PA: W.B. Saunders Company; 1999. p. 409-439.","DOI":"10.1097\/00024382-199910000-00017"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Peltola H, Karanko V, Kurki T, et al. Rapid effect on endemic measles, mumps, and rubella of nationwide vaccination programme in Finland. Lancet. 1986;327:137-9.","DOI":"10.1016\/S0140-6736(86)92270-1"},{"key":"5","unstructured":"5. McLean HQ, Fiebelkorn AP, Temte JL, et al. Prevention of measles, rubella, congenital rubella syndrome, and mumps, 2013: summary recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2013;62(RR-04):1-34."},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Saitoh A, Okabe N. Recent progress and concerns regarding the Japanese immunization program: addressing the "vaccine gap". Vaccine. 2014;32:4253-8.","DOI":"10.1016\/j.vaccine.2014.06.022"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Kimura M, Kuno-Sakai H, Yamazaki S, et al. Adverse events associated with MMR vaccines in Japan. Acta Paediatr Jpn. 1996;38:205-11.","DOI":"10.1111\/j.1442-200X.1996.tb03471.x"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Andreae MC, Freed GL, Katz SL. Safety concerns regarding combination vaccines: the experience in Japan. Vaccine. 2004;22:3911-6.","DOI":"10.1016\/j.vaccine.2004.04.013"},{"key":"9","unstructured":"9. Centers for Disease Control and Prevention (CDC). Progress toward measles elimination---Japan, 1999--2008. MMWR Morb Mortal Wkly Rep. 2008:57;1049-52."},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Sawada A, Yamaji Y, Nakayama T. Mumps Hoshino and Torii vaccine strains were distinguished from circulating wild strains. J Infect Chemother. 2013;19:480-5.","DOI":"10.1007\/s10156-012-0515-3"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Tsuchiya Y, Shida N, Izumi S, et al. Factors associated with mothers not vaccinating their children against mumps in Japan. Public Health. 2016;137:95-105.","DOI":"10.1016\/j.puhe.2016.03.002"},{"key":"12","unstructured":"12. Nakatani H, Sano T, Iuchi T. Development of vaccination policy in Japan: current issues and policy directions. Jpn J Infect Dis. 2002;55:101-11."},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Sugishita Y, Kurita J, Akagi T, et al. Determinants of vaccination coverage for the second dose of measles-rubella vaccine in Tokyo, Japan. Tohoku J Exp Med. 2019;249:265-73.","DOI":"10.1620\/tjem.249.265"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Ueda K, Miyazaki C, Hidaka Y, et al. Aseptic meningitis caused by measles-mumps-rubella vaccine in Japan. Lancet. 1995;346:701-2.","DOI":"10.1016\/S0140-6736(95)92311-X"},{"key":"15","unstructured":"15. Centers for Disease Control and Prevention (CDC). Measles - United States, 2011. MMWR Morb Mortal Wkly Rep. 2012;61:253-7."},{"key":"16","unstructured":"16. Centers for Disease Control and Prevention (CDC). Elimination of rubella and congenital rubella syndrome---United States, 1969--2004. MMWR Morb Mortal Wkly Rep. 2005;54:279-82."},{"key":"17","unstructured":"17. Centers for Disease Control and Prevention (CDC). Mumps Cases and Outbreaks. Available at <https:\/\/www.cdc.gov\/mumps\/outbreaks.html>. Accessed March 7, 2020."},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Miller E, Goldacre M, Pugh S, et al. Risk of aseptic meningitis after measles, mumps, and rubella vaccine in UK children. Lancet. 1993;341:979-82.","DOI":"10.1016\/0140-6736(93)91069-X"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Black S, Shinefield H, Ray P, et al. Risk of hospitalization because of aseptic meningitis after measles-mumps-rubella vaccination in one- to two-year-old children: an analysis of the Vaccine Safety Datalink (VSD) Project. Pediatr Infect Dis J. 1997;16:500-3.","DOI":"10.1097\/00006454-199705000-00009"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Usonis V, Bakasenas V, Kaufhold A, et al. Reactogenicity and immunogenicity of a new live attenuated combined measles, mumps and rubella vaccine in healthy children. Pediatr Infect Dis J.1999;18:42-8.","DOI":"10.1097\/00006454-199901000-00011"},{"key":"21","unstructured":"21. Hirayama M, Kimura M, Kimura K, et al. Comparative clinical study of measles vaccine Schwarz FF-8 strain and AIK-C strain (Kitasato Laboratory). Clinical Virology. 1982;10:245-53. Japanese."},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Dunnett CW, Gent M. Significance testing to establish equivalence between treatments, with special reference to data in the form of 2x2 tables. Biometrics. 1977;33:593-602.","DOI":"10.2307\/2529457"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Schwarzer S, Reibel S, Laug AB, et al. Safety and characterization of the immune response engendered by two combined measles, mumps and rubella vaccines. Vaccine. 1998;16:298-304.","DOI":"10.1016\/S0264-410X(97)00174-6"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Demicheli V, Rivetti A, Debalini MG, et al. Vaccines for measles, mumps and rubella in children. Cochrane Database Syst Rev. 2012;2012:CD004407.","DOI":"10.1002\/14651858.CD004407.pub3"},{"key":"25","unstructured":"25. Kimura M, Hirayama M, Sakai H. Points to note by vaccine. In: Kimura M, Hirayama M, Sakai H, editors. Guidance of Vaccination. 8th ed. Tokyo, Japan: Kindai Press; 2000. p. 177-87. Japanese."},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. Sugiura A, Yamada A. Aseptic meningitis as a complication of mumps vaccination. Pediatr Infect Dis J. 1991;10:209-13.","DOI":"10.1097\/00006454-199103000-00008"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27. Yawata M. Japan's troubles with measles-mumps-rubella vaccine. Lancet. 1994;343:105-6. Available at <https:\/\/doi.org\/10.1016\/S0140-6736(94)90826-5>. Accessed June 3, 2021.","DOI":"10.1016\/S0140-6736(94)90826-5"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28. Lievano F, Galea SA, Thornton M, et al. Measles, mumps, and rubella virus vaccine (M-M-R\u2122II): a review of 32 years of clinical and postmarketing experience. Vaccine. 2012;30:6918-26.","DOI":"10.1016\/j.vaccine.2012.08.057"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29. Carazo Perez S, Bureau A, De Serres G. Post-immunisation fever and the antibody response to measles-containing vaccines. Epidemiol Infect. 2018;146:1584-92.","DOI":"10.1017\/S0950268818001474"}],"container-title":["Japanese Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/yoken\/74\/5\/74_JJID.2020.876\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,13]],"date-time":"2022-12-13T20:39:43Z","timestamp":1670963983000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/yoken\/74\/5\/74_JJID.2020.876\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,30]]},"references-count":29,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.7883\/yoken.jjid.2020.876","relation":{},"ISSN":["1344-6304","1884-2836"],"issn-type":[{"value":"1344-6304","type":"print"},{"value":"1884-2836","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,30]]},"article-number":"JJID.2020.876"}}